SRPT - Sarepta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 511.42B
Enterprise Value 310.52B
Trailing P/E N/A
Forward P/E 1-52.03
PEG Ratio (5 yr expected) 1163.80
Price/Sales (ttm)35.31
Price/Book (mrq)8.47
Enterprise Value/Revenue 332.52
Enterprise Value/EBITDA 6-28.22

Trading Information

Stock Price History

Beta (3Y Monthly) 1.78
52-Week Change 313.07%
S&P500 52-Week Change 37.12%
52 Week High 3165.87
52 Week Low 395.21
50-Day Moving Average 3134.26
200-Day Moving Average 3127.30

Share Statistics

Avg Vol (3 month) 31.15M
Avg Vol (10 day) 31.07M
Shares Outstanding 565.53M
Float 70.32M
% Held by Insiders 15.25%
% Held by Institutions 192.55%
Shares Short (Jun 28, 2019) 411.77M
Short Ratio (Jun 28, 2019) 49.4
Short % of Float (Jun 28, 2019) 419.72%
Short % of Shares Outstanding (Jun 28, 2019) 415.87%
Shares Short (prior month May 31, 2019) 410.18M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 26/1
Last Split Date 3Jul 12, 2012

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin -124.66%
Operating Margin (ttm)-119.84%

Management Effectiveness

Return on Assets (ttm)-14.84%
Return on Equity (ttm)-37.94%

Income Statement

Revenue (ttm)323.44M
Revenue Per Share (ttm)4.76
Quarterly Revenue Growth (yoy)34.70%
Gross Profit (ttm)-131.1M
EBITDA -372.73M
Net Income Avi to Common (ttm)-403.2M
Diluted EPS (ttm)-5.93
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.39B
Total Cash Per Share (mrq)18.7
Total Debt (mrq)484.68M
Total Debt/Equity (mrq)35.94
Current Ratio (mrq)12.17
Book Value Per Share (mrq)18.19

Cash Flow Statement

Operating Cash Flow (ttm)-499.22M
Levered Free Cash Flow (ttm)-331.29M